4.7 Article

Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals

期刊

CARDIOVASCULAR RESEARCH
卷 117, 期 6, 页码 1523-1531

出版社

OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvaa241

关键词

Atrial fibrillation; Epidemiology; CLSA

资金

  1. Canadian Cardiovascular Society Atrial Fibrillation Award
  2. Canadian Institutes for Health Research [149065]
  3. Population Health Research Institute
  4. Heart and Stroke Foundation of Ontario
  5. Astra Zeneca (Canada)
  6. SanofiAventis (France)
  7. Boehringer Ingelheim (Germany)
  8. Servier
  9. GSK
  10. Marion Burke Chair of the Heart and Stroke Foundation of Canada
  11. Raymond and Margaret Labarge Chair in Optimal Aging and Knowledge Application for Optimal Aging
  12. Tier 1 Canada Research Chair in Geroscience
  13. Saudi Heart Association
  14. Saudi Gastroenterology Association
  15. Dr. Mohammad Alfagih Hospital
  16. Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia [RG-1436-013]
  17. Novartis
  18. King Pharma

向作者/读者索取更多资源

This study compares the prevalence of atrial fibrillation (AF) across eight regions and shows significant variations in different income level countries and regions. Despite traditional risk factors, antithrombotic therapy is infrequently used in poorer countries, highlighting the disproportionate risk associated with AF.
Aims To compare the prevalence of electrocardiogram (ECG)-documented atrial fibrillation (or flutter) (AF) across eight regions of the world, and to examine antithrombotic use and clinical outcomes. Methods and results Baseline ECGs were collected in 153 152 middle-aged participants (ages 35-70 years) to document AF in two community-based studies, spanning 20 countries. Medication use and clinical outcome data (mean follow-up of 7.4 years) were available in one cohort. Cross-sectional analyses were performed to document the prevalence of AF and medication use, and associations between AF and clinical events were examined prospectively. Mean age of participants was 52.1 years, and 57.7% were female. Age and sex-standardized prevalence of AF varied 12-fold between regions; with the highest in North America, Europe, China, and Southeast Asia (270-360 cases per 100 000 persons); and lowest in the Middle East, Africa, and South Asia (30-60 cases per 100 000 persons) (P < 0.001). Compared with low-income countries (LICs), AF prevalence was 7-fold higher in middle-income countries (MICs) and 11-fold higher in high-income countries (HICs) (P < 0.001). Differences in AF prevalence remained significant after adjusting for traditional AF risk factors. In LICs/MICs, 24% of participants with AF and a CHADS2 score >= 1 received antithrombotic therapy, compared with 85% in HICs. AF was associated with an increased risk of stroke [hazard ratio (HR) 2.29; 95% confidence interval (CI) 1.49-3.52] and death (HR 2.97; 95% CI 2.25-3.93); with similar rates in different countries grouped by income level. Conclusions Large variations in AF prevalence occur in different regions and countries grouped by income level, but this is only partially explained by traditional AF risk factors. Antithrombotic therapy is infrequently used in poorer countries despite the high risk of stroke associated with AF. [GRAPHICS] .

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据